Escrow Agreement FOR SECURITIES OFFERINGEscrow Agreement • January 12th, 2023 • CancerVAX, Inc. • Delaware
This Escrow Agreement, effective as of _____________, (“Escrow Agreement”), is by, between and among The Bryn Mawr Trust Company of Delaware, a Delaware Limited Purpose Trust Company and located at 20 Montchanin Rd., Suite 100, Greenville, DE 19807 as Escrow Agent hereunder (“Escrow Agent”); StartEngine Primary LLC (“Broker”), a Delaware Limited Liability Company, located at 4100 W. Alameda Ave, 3rd floor Burbank, CA 91505 ; and ____________________________, a __________________________ (“Issuer”) located at ___________________________________________________________________.
COMMON STOCK SUBSCRIPTION AGREEMENTCommon Stock Subscription Agreement • February 14th, 2024 • CancerVAX, Inc. • Pharmaceutical preparations • Nevada
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
INDEPENDENT CONTRACTOR AGREEMENTIndependent Contractor Agreement • December 8th, 2023 • CancerVAX, Inc. • Pharmaceutical preparations • Nevada
This INDEPENDENT CONTRACTOR AGREEMENT (the “Agreement”) is by and between Carla Miller, an individual (the “Contractor”), and CancerVAX, Inc., a Nevada corporation (the “Company”), effective the 1st day of April 2021, the date the Services (as defined below) were first provided by Contractor (the “Effective Date).
Broker-Dealer AgreementBroker-Dealer Agreement • March 11th, 2024 • CancerVAX, Inc. • Pharmaceutical preparations
This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between CancerVAX, Inc (“Client”) and Dalmore Group, LLC., a Delaware Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of 10-23-2023 (the “Effective Date”):
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 11th, 2024 • CancerVAX, Inc. • Pharmaceutical preparations • Nevada
THIS SECURITIES PURCHASE AGREEMENT (“Agreement”) is entered into as of March 30, 2021, by and between CancerVAX, Inc., a Nevada corporation (the “Company”), and Bountiful Capital, LLC, a Nevada limited liability company, (the “Investor”), with respect to the following facts:
COMMON STOCK SUBSCRIPTION AGREEMENTCommon Stock Subscription Agreement • March 11th, 2024 • CancerVAX, Inc. • Pharmaceutical preparations • Nevada
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • March 11th, 2024 • CancerVAX, Inc. • Pharmaceutical preparations • California
This Investor Rights Agreement (this “Agreement”), is made as of October 1, 2021, by and among CancerVAX, Inc., a Nevada corporation (the “Company”), Bountiful Capital, LLC, a Nevada limited liability company (“Investor”), and each of the stockholders listed on Schedule A hereto, each of whom is referred to herein as a “Key Holder”.
SUBSCRIPTION AGREEMENT Offering Series B Preferred Shares in CANCERVAX, INC. Second Floor Santa Barbara, California 93101 $5,000,000 Offering Maximum $100,000 Minimum Investment Amount No Minimum Raise AmountSubscription Agreement • March 11th, 2024 • CancerVAX, Inc. • Pharmaceutical preparations • Nevada
THIS SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is made this 13th day of October, 2023 by and between CancerVAX, Inc., a Nevada corporation (hereinafter the “Issuer” or “Company”), and the undersigned subscriber (the “Subscriber”), who, for and in consideration of the mutual promises and covenants set forth herein, do hereto agree as follows:
CancerVax, Inc. SUBSCRIPTION AGREEMENT SIGNATURE PAGESubscription Agreement • January 12th, 2023 • CancerVAX, Inc.
I, the undersigned, desiring to purchase shares of Common Stock of CancerVax, Inc. by executing this signature page, hereby executes, adopts and agrees to all terms, conditions, and representations of the Subscription Agreement.
INDEPENDENT CONTRACTOR AGREEMENTIndependent Contractor Agreement • March 11th, 2024 • CancerVAX, Inc. • Pharmaceutical preparations • Nevada
This INDEPENDENT CONTRACTOR AGREEMENT (the “Agreement”) is by and between Carla Miller, an individual (the “Contractor”), and CancerVAX, Inc., a Nevada corporation (the “Company”), effective the 1st day of April 2021, the date the Services (as defined below) were first provided by Contractor (the “Effective Date).
